Aardvark Therapeutics clinical trials we track

Check company identity source

Phase 3 2 trials

Phase 2 4 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters
A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

NCT05153434 · Aardvark Therapeutics, Inc.

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of Treatment-Emergent Adverse Events (TEAE). After: Measure: Incidence of Treatment Emergent Adverse Events (TEAE).

Check registry source

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 90 participants (planned). After: 19 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Mar 2027. After: 15 Apr 2026.

Recruitment status changed

Before: Suspended. After: Terminated.

Check registry source

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 90 participants (planned). After: 68 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Mar 2027. After: 7 May 2026.

Recruitment status changed

Before: Suspended. After: Terminated.

Check registry source